• <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
      <b id="1ykh9"><small id="1ykh9"></small></b>
    1. <b id="1ykh9"></b>

      1. <button id="1ykh9"></button>
        <video id="1ykh9"></video>
      2. west china medical publishers
        Author
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Author "何宇" 2 results
        • Preliminary Study of Correlation Between Androgen or Stathmin Expression in Patients with Triple Negative Breast Cancer and Its Clinicopathologic Factors

          Objective To explore the expressions of androgen (AR) and Stathmin in triple negative breast cancer (TNBC) and analyze the correlation between these expressions and clinicopathologic features. Methods Eighty-three patients who were diagnosed as TNBC and met the inclusion criteria from 2005 to 2009 in the Sichuan Provincial People’s Hospital were collected retrospectively. The expressions of AR and Stathmin in the TNBC tissues by using the method of EnVision immunohistochemistry. The correlation between AR or Stathmin expression and age, tumor size, lymph node status, or histological grade was analyzed by Spearman test. Results The AR and Stathmin positive expression rates in the patients with TNBC were 37.3% (31/83) and 98.8% (82/83), respectively. The AR expression was positively correlated with age(rs=0.302, P=0.006)and pathological grade (rs=0.225, P=0.041), but was not correlated with tumor size or lymph node status. The Stathmin expression was not correlated with age, tumor size, lymph node status, or pathological grade (P>0.05) . Conclusions The AR expression is correlated with the age or pathological grade but Stathmin expression was all not correlated with the clinicopathologic features. AR or Stathmin as a prognosis indicator in patients with TNBC are needed to more research.

          Release date:2016-09-08 10:35 Export PDF Favorites Scan
        • 狄諾塞麥在乳腺癌中的應用

          【摘要】 狄諾塞麥是目前第一個也是唯一獲批的特異性靶向核因子κB受體活化因子配體抑制劑類藥物。在乳腺癌的治療中,無論是對于癌癥治療相關性的骨質疏松或者骨轉移,狄諾塞麥都能起到很好的治療作用,具有廣闊的應用前景。現就狄諾塞麥的藥理特性、治療機制、臨床試驗及效果作一闡述。

          Release date:2016-09-08 09:26 Export PDF Favorites Scan
        1 pages Previous 1 Next

        Format

        Content

      3. <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
          <b id="1ykh9"><small id="1ykh9"></small></b>
        1. <b id="1ykh9"></b>

          1. <button id="1ykh9"></button>
            <video id="1ykh9"></video>
          2. 射丝袜